Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$7.97 +1.97%

+$0.15 today

Market cap
$229.72M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.45M

Average 0.43M

Returns on capital

Arcturus Therapeutics Holdings Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-30.7%

avg -50.2%

ROIC

-31.4%

avg -34.8%

ROA

-24.3%

avg -26.9%

Analysis

ROA is currently the strongest return metric at -24.3% versus its period average of -26.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joseph E. Payne

Founder, President, Chief Executive Officer & DirectorUSD 750K54175.00K0.62%

Padmanabh Chivukula

Founder, Chief Scientific Officer, Chief Operating Officer & SecretaryUSD 572K47——

Lance Kurata

Chief Legal OfficerUSD 540K—54.00K0.19%

Joseph Roberts

Principal Accounting Officer & ControllerUSD 219.58K4310.00K0.04%

Igor Smolenov

Chief Development Officer————

Ye Zhang

Chief Regulatory & Quality Assurance Officer————

Dennis Mulroy

Chief Financial Officer—710<0.01%

Kevin T. Skol

Chief Business Officer————

Natash O. Bowman

Chief Human Resources Officer————

Neda Safarzadeh

Vice President and Head of IR/PR & Marketing————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A-31.1%
+37.7% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -31.1% over three years. Forward estimates point to Revenue at +37.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Arcturus Therapeutics Holdings Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ARCT's management, answered from reported figures.

Who manages ARCT?

Arcturus Therapeutics Holdings Inc. (ARCT) lists 10 active executives. The top listed executive is Igor Smolenov, Chief Development Officer.

Are ARCT insiders buying or selling?

Recent insider activity shows net selling of $31.60M.